CME Session
Hybrid Session
Walter Stadler, MD
University of Chicago
Chicago, Illinois, United States
Disclosure: Disclosure(s): Consulting - Early phase drug development: Calico Life Sciences (Terminated, December 31, 2021)
Contract Research: Amgen (Ongoing); BMS (Ongoing); Calithera (Ongoing); Corvus (Ongoing); Merck (Ongoing); Pfizer (Ongoing); Roche/Genentech (Ongoing)
DSMB - bladder cancer: Astra-Zeneca (Ongoing)
DSMB - Phase 1: Treadwell Therapeutics (Ongoing)
DSMB - prostate cancer: Bayer (Ongoing); Merck (Ongoing); Pfizer (Ongoing)
Non-CE Consulting: Caremark/CVS (Ongoing); EMA Wellnes (Ongoing)